[en] Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect.
Disciplines :
General & internal medicine
Author, co-author :
Body, J. J.
Bergmann, P.
Boonen, S.
Boutsen, Y.
Devogelaer, J. P.
Goemaere, S.
Kaufman, J. M.
Rozenberg, S.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.
Publication date :
2010
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science & Business Media B.V., Godalming, United Kingdom
Cummings, S.R., Black, D.M., Rubin, S.M., Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women (1989) Arch Intern Med, 149, pp. 2445-2448. , 1:STN:280:DyaK3c%2FlsFGgsQ%3D%3D 2818106
Autier, P., Haentjens, P., Bentin, J., Baillon, J.M., Grivegnee, A.R., Closon, M.C., Boonen, S., Costs induced by hip fractures: A prospective controlled study in Belgium (2000) Belgian Hip Fracture Study Group. Osteoporos Int, 11, pp. 373-380. , 1:STN:280:DC%2BD3cvgvFeltg%3D%3D
Cranney, A., Tugwell, P., Wells, G., Guyatt, G., Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: Introduction and methodology (2002) Endocr Rev, 23, pp. 496-507. , 12202464
Kanis, J.A., Burlet, N., Cooper, C., Delmas, P.D., Reginster, J.Y., Borgstrom, F., Rizzoli, R., European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008) Osteoporos Int, 19, pp. 399-428. , 1:STN:280:DC%2BD1c3itFekuw%3D%3D 18266020
Boonen, S., Body, J.J., Boutsen, Y., Devogelaer, J.P., Goemaere, S., Kaufman, J.M., Rozenberg, S., Reginster, J.Y., Evidence-based guidelines for the treatment of postmenopausal osteoporosis: A consensus document of the Belgian Bone Club (2005) Osteoporos Int, 16, pp. 239-254. , 15726235
Kanis, J.A., Burlet, N., Cooper, C., Delmas, P.D., Reginster, J.Y., Borgstrom, F., Rizzoli, R., European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008) Osteoporos Int, 19, pp. 399-428. , European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). 1:STN:280:DC%2BD1c3itFekuw%3D%3D 18266020
Neuprez, A., Johansson, H., Kanis, J.A., McCloskey, E.V., Oden, A., Bruyere, O., Hiligsmann, M., Reginster, J.Y., Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX® (2009) Rev Med Liege, 64, pp. 612-619. , 1:STN:280:DC%2BC3c%2Fps12gtw%3D%3D 20143744
Rizzoli, R., Boonen, S., Brandi, M.L., Burlet, N., Delmas, P., Reginster, J.Y., The role of calcium and vitamin D in the management of osteoporosis (2008) Bone, 42, pp. 246-249. , 1:CAS:528:DC%2BD1cXls1eiuw%3D%3D 18055288
Boonen, S., Bischoff-Ferrari, H.A., Cooper, C., Lips, P., Ljunggren, O., Meunier, P.J., Reginster, J.Y., Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence (2006) Calcif Tissue Int, 78, pp. 257-270. , 1:CAS:528:DC%2BD28XksFSgsrc%3D 16622587
Optimal calcium intake. NIH consensus development panel on optimal calcium intake (1994) JAMA, 272, pp. 1942-1948. , NIH Consensus conference
Thomas, S.D., Need, A.G., Tucker, G., Slobodian, P., O'Loughlin, P.D., Nordin, B.E., Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women (2008) Calcif Tissue Int, 83, pp. 81-84. , 1:CAS:528:DC%2BD1cXhtVyju7fF 18553042
Deprez, X., Fardellone, P., Nonpharmacological prevention of osteoporotic fractures (2003) Joint Bone Spine, 70, pp. 448-457. , 14667552
Lips, P., Bouillon, R., Van Schoor, N., Vanderschueren, D., Verschueren, S., Kuchuk, N., Milisen, K., Boonen, S., Reducing fracture risk with calcium and vitamin D (2009) Clin Endocrinol, , doi: 10.1111/j.0300-0664.2009.03701.x
Chapuy, M.C., Arlot, M.E., Duboeuf, F., Brun, J., Crouzet, B., Arnaud, S., Delmas, P.D., Meunier, P.J., Vitamin D3 and calcium to prevent hip fractures in the elderly women (1992) N Engl J Med, 327, pp. 1637-1642. , 1:STN:280:DyaK3s%2FmtlSrug%3D%3D 1331788
Chapuy, M.C., Arlot, M.E., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women (1994) BMJ, 308, pp. 1081-1082. , 1:STN:280:DyaK2c3islKnuw%3D%3D 8173430
Chapuy, M.C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., Garnero, P., Meunier, P.J., Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study (2002) Osteoporos Int, 13, pp. 257-264. , 1:CAS:528:DC%2BD38XksVynt7g%3D 11991447
Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676. , 1:CAS:528:DyaK2sXmt1Wqtbk%3D 9278463
Lips, P., Graafmans, W.C., Ooms, M.E., Bezemer, P.D., Bouter, L.M., Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial (1996) Ann Intern Med, 124, pp. 400-406. , 1:STN:280:DyaK287ltF2nsQ%3D%3D 8554248
Trivedi, D.P., Doll, R., Khaw, K.T., Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial (2003) BMJ, 326, p. 469. , 1:CAS:528:DC%2BD3sXisFart7Y%3D 12609940
Heikinheimo, R.J., Inkovaara, J.A., Harju, E.J., Haavisto, M.V., Kaarela, R.H., Kataja, J.M., Kokko, A.M., Rajala, S.A., Annual injection of vitamin D and fractures of aged bones (1992) Calcif Tissue Int, 51, pp. 105-110. , 1:CAS:528:DyaK38XlvVCltrc%3D 1422948
Bischoff-Ferrari, H.A., Willett, W.C., Wong, J.B., Giovannucci, E., Dietrich, T., Dawson-Hughes, B., Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials (2005) JAMA, 293, pp. 2257-2264. , 1:CAS:528:DC%2BD2MXktFOntb8%3D 15886381
Boonen, S., Lips, P., Bouillon, R., Bischoff-Ferrari, H.A., Vanderschueren, D., Haentjens, P., Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: Evidence from a comparative metaanalysis of randomized controlled trials (2007) J Clin Endocrinol Metab, 92, pp. 1415-1423. , 1:CAS:528:DC%2BD2sXksVSrt7k%3D 17264183
Bischoff-Ferrari, H.A., Willett, W.C., Wong, J.B., Stuck, A.E., Staehelin, H.B., Orav, E.J., Thoma, A., Henschkowski, J., Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials (2009) Arch Intern Med, 169, pp. 551-561. , 1:CAS:528:DC%2BD1MXksVOntr4%3D 19307517
Tang, B.M., Eslick, G.D., Nowson, C., Smith, C., Bensoussan, A., Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis (2007) Lancet, 370, pp. 657-666. , 1:CAS:528:DC%2BD2sXpsFWrsbc%3D 17720017
Adami, S., Isaia, G., Luisetto, G., Minisola, S., Sinigaglia, L., Gentilella, R., Agnusdei, D., Nuti, R., Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study (2006) J Bone Miner Res, 21, pp. 1565-1570. , 1:CAS:528:DC%2BD28XhtFekt7zN 16995811
Rossini, M., Bianchi, G., Di Munno, O., Giannini, S., Minisola, S., Sinigaglia, L., Adami, S., Determinants of adherence to osteoporosis treatment in clinical practice (2006) Osteoporos Int, 17, pp. 914-921. , 1:STN:280:DC%2BD283osVKltg%3D%3D 16538553
Rozenberg, S., Vandromme, J., Kroll, M., Pastijn, A., Degueldre, M., Osteoporosis prevention with sex hormone replacement therapy (1994) Int J Fertil Menopausal Stud, 39, pp. 262-271. , 1:STN:280:DyaK2M7itVShsQ%3D%3D 7820159
Rossouw, J.E., Anderson, G.L., Prentice, R.L., Lacroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Ockene, J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial (2002) JAMA, 288, pp. 321-333. , 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397
Scarabin, P.Y., Oger, E., Plu-Bureau, G., Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk (2003) Lancet, 362, pp. 428-432. , 1:CAS:528:DC%2BD3sXmt1ajsr0%3D 12927428
Canonico, M., Bouaziz, E., Carcaillon, L., Verstuyft, C., Guiochon-Mantel, A., Becquemont, L., Scarabin, P.Y., Synergism between oral estrogen therapy and cytochrome P450 3A5 1 allele on the risk of venous thromboembolism among postmenopausal women (2008) J Clin Endocrinol Metab, 93, pp. 3082-3087. , Estrogen and Thromboembolism Risk (ESTHER) Study Group. 1:CAS:528:DC%2BD1cXpvVOlsrg%3D 18628519
Cummings, S.R., Ettinger, B., Delmas, P.D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Eastell, R., The effects of tibolone in older postmenopausal women (2008) N Engl J Med, 359, pp. 697-708. , 1:CAS:528:DC%2BD1cXpvFyksL0%3D 18703472
Gompel, A., Rozenberg, S., Barlow, D.H., The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy (2008) Maturitas, 61, pp. 227-232. , 1:CAS:528:DC%2BD1cXhsVeru7rN 19028033
Lekander, I., Borgström, F., Ström, O., Zethraeus, N., Kanis, J.A., Cost-effectiveness of hormone therapy in the United States (2009) J Womens Health (Larchmt), 10, pp. 1669-1677
Bagger, Y.Z., Tanko, L.B., Alexandersen, P., Hansen, H.B., Mollgaard, A., Ravn, P., Qvist, P., Christiansen, C., Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study (2004) Bone, 34, pp. 728-735. , 1:CAS:528:DC%2BD2cXisF2ntb0%3D 15050905
Alexandersen, P., Toussaint, A., Christiansen, C., Devogelaer, J.P., Roux, C., Fechtenbaum, J., Gennari, C., Reginster, J.Y., Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial (2001) JAMA, 285, pp. 1482-1488. , 1:CAS:528:DC%2BD3MXis1CjsLg%3D 11255425
Alekel, D.L., Germain, A.S., Peterson, C.T., Hanson, K.B., Stewart, J.W., Toda, T., Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women (2000) Am J Clin Nutr, 72, pp. 844-852. , 1:CAS:528:DC%2BD3cXmsFGrt7Y%3D 10966908
Hsu, C.S., Shen, W.W., Hsueh, Y.M., Yeh, S.L., Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density (2001) J Reprod Med, 46, pp. 221-226. , 1:CAS:528:DC%2BD3MXjtVOhurs%3D 11304862
Chen, Y.M., Ho, S.C., Lam, S.S., Ho, S.S., Woo, J.L., Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: A double-blind, randomized, controlled trial (2003) J Clin Endocrinol Metab, 88, pp. 4740-4747. , 1:CAS:528:DC%2BD3sXoslemt7Y%3D 14557449
Kreijkamp-Kaspers, S., Kok, L., Grobbee, D.E., De Haan, E.H., Aleman, A., Lampe, J.W., Van Der Schouw, Y.T., Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial (2004) JAMA, 292, pp. 65-74. , 1:CAS:528:DC%2BD2cXls1elsL8%3D 15238592
Nikander, E., Metsa-Heikkila, M., Ylikorkala, O., Tiitinen, A., Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer (2004) J Clin Endocrinol Metab, 89, pp. 1207-1212. , 1:CAS:528:DC%2BD2cXisVWru74%3D 15001611
Seeman, E., Crans, G.G., Diez-Perez, A., Pinette, K.V., Delmas, P.D., Anti-vertebral fracture efficacy of raloxifene: A meta-analysis (2006) Osteoporos Int, 17, pp. 313-316. , 16217588
Recker, R.R., Kendler, D., Recknor, C.P., Rooney, T.W., Lewiecki, E.M., Utian, W.H., Cauley, J.A., Stock, J.L., Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass (2007) Bone, 40, pp. 843-851. , 1:CAS:528:DC%2BD2sXjtVaktrk%3D 17182297
Martino, S., Cauley, J.A., Barrett-Connor, E., Powles, T.J., Mershon, J., Disch, D., Secrest, R.J., Cummings, S.R., Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene (2004) J Natl Cancer Inst, 96, pp. 1751-1761. , 1:CAS:528:DC%2BD2cXhtVCrsrjM 15572757
Siris, E.S., Harris, S.T., Eastell, R., Zanchetta, J.R., Goemaere, S., Diez-Perez, A., Stock, J.L., Cummings, S.R., Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study (2005) J Bone Miner Res, 20, pp. 1514-1524. , 1:CAS:528:DC%2BD2MXhtVOltrrP 16059623
Neele, S.J., Evertz, R., De Valk-De, R.G., Roos, J.C., Netelenbos, J.C., Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women (2002) Bone, 30, pp. 599-603. , 1:CAS:528:DC%2BD38XisV2ksb4%3D 11934652
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M.J., Grady, D., Kornitzer, M., McNabb, M.A., Wenger, N.K., Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women (2006) N Engl J Med, 355, pp. 125-137. , 1:CAS:528:DC%2BD28Xmsl2ktrs%3D 16837676
Vogel, V.G., Costantino, J.P., Wickerham, D.L., Cronin, W.M., Cecchini, R.S., Atkins, J.N., Bevers, T.B., Wolmark, N., Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial (2006) JAMA, 295, pp. 2727-2741. , 1:CAS:528:DC%2BD28XmtFOltLc%3D 16754727
Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Favus, M., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group (1995) N Engl J Med, 333, pp. 1437-1443. , 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143
Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., Bauer, D.C., Ensrud, K.E., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group (1996) Lancet, 348, pp. 1535-1541. , 1:CAS:528:DyaK2sXisFCktQ%3D%3D 8950879
Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Lacroix, A.Z., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial (1998) JAMA, 280, pp. 2077-2082. , 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874
Karpf, D.B., Shapiro, D.R., Seeman, E., Ensrud, K.E., Johnston Jr., C.C., Adami, S., Harris, S.T., Thompson, D., Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups (1997) JAMA, 277, pp. 1159-1164. , 1:CAS:528:DyaK2sXis1eqsb8%3D 9087473
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Guyatt, G., Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women (2002) Endocr Rev, 23, pp. 508-516. , 1:CAS:528:DC%2BD38Xnt1Wiur8%3D 12202465
Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Liberman, U.A., Ten years' experience with alendronate for osteoporosis in postmenopausal women (2004) N Engl J Med, 350, pp. 1189-1199. , 1:CAS:528:DC%2BD2cXit12rsLc%3D 15028823
Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A., Satterfield, S., Cummings, S.R., Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial (2006) JAMA, 296, pp. 2927-2938. , 1:CAS:528:DC%2BD2sXnvVGh 17190893
De Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Wang, K.K., Esophagitis associated with the use of alendronate (1996) N Engl J Med, 335, pp. 1016-1021. , 8793925
Schnitzer, T., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Orloff, J.J., Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group (2000) Aging (Milano), 12, pp. 1-12. , 1:CAS:528:DC%2BD3cXitVCns7g%3D
Dansereau, R.J., Crail, D.J., Perkins, A.C., In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US (2009) Curr Med Res Opin, 25, pp. 449-452. , 1:CAS:528:DC%2BD1MXltVWms7c%3D 19192989
Perkins, A.C., Blackshaw, P.E., Hay, P.D., Lawes, S.C., Atherton, C.T., Dansereau, R.J., Wagner, L.K., Spiller, R.C., Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects (2008) Clin Ther, 30, pp. 834-844. , 1:CAS:528:DC%2BD1cXhtValsr3J 18555931
Ringe, J.D., Moller, G., Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis (2009) Rheumatol Int., , doi: 10.1007/s00296-009-0940-5
Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M., Chesnut III, C.H., Miller, P.D., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (1999) JAMA, 282, pp. 1344-1352. , 1:CAS:528:DyaK1MXmvFansr0%3D 10527181
Reginster, J., Minne, H.W., Sorensen, O.H., Hooper, M., Roux, C., Brandi, M.L., Lund, B., Eastell, R., Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group (2000) Osteoporos Int, 11, pp. 83-91. , 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10663363
Watts, N.B., Josse, R.G., Hamdy, R.C., Hughes, R.A., Manhart, M.D., Barton, I., Calligeros, D., Felsenberg, D., Risedronate prevents new vertebral fractures in postmenopausal women at high risk (2003) J Clin Endocrinol Metab, 88, pp. 542-549. , 1:CAS:528:DC%2BD3sXhtlChsLg%3D 12574177
Harrington, J.T., Ste-Marie, L.G., Brandi, M.L., Civitelli, R., Fardellone, P., Grauer, A., Barton, I., Boonen, S., Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis (2004) Calcif Tissue Int, 74, pp. 129-135. , 1:CAS:528:DC%2BD2cXhtFGjt78%3D 14648009
Sorensen, O.H., Crawford, G.M., Mulder, H., Hosking, D.J., Gennari, C., Mellstrom, D., Pack, S., Reginster, J.Y., Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience (2003) Bone, 32, pp. 120-126. , 1:CAS:528:DC%2BD3sXhvFWqu7o%3D 12633783
Boonen, S., McClung, M.R., Eastell, R., El-Hajj Fuleihan, G., Barton, I.P., Delmas, P., Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old (2004) J Am Geriatr Soc, 52, pp. 1832-1839. , 15507059
McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C., Adami, S., Reginster, J.Y., Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group (2001) N Engl J Med, 344, pp. 333-340. , 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 11172164
Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Guyatt, G., Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis (2002) Endocr Rev, 23, pp. 517-523. , 1:CAS:528:DC%2BD38Xnt1Wiurs%3D 12202466
Brown, J.P., Kendler, D.L., McClung, M.R., Emkey, R.D., Adachi, J.D., Bolognese, M.A., Li, Z., Lindsay, R., The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis (2002) Calcif Tissue Int, 71, pp. 103-111. , 1:CAS:528:DC%2BD38Xms1emurY%3D 12085156
Chesnut, I.C., Skag, A., Christiansen, C., Recker, R., Stakkestad, J.A., Hoiseth, A., Felsenberg, D., Delmas, P.D., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis (2004) J Bone Miner Res, 19, pp. 1241-1249. , 1:CAS:528:DC%2BD2cXntFGqurw%3D
Reginster, J.Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J.J., Silverman, S.L., Christiansen, C., Miller, P.D., Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (2006) Ann Rheum Dis, 65, pp. 654-661. , 1:CAS:528:DC%2BD28XkvFyqur0%3D 16339289
Stakkestad, J.A., Lakatos, P., Lorenc, R., Sedarati, F., Neate, C., Reginster, J.Y., Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension (2008) Clin Rheumatol, 27, pp. 955-960. , 18180976
Delmas, P.D., Adami, S., Strugala, C., Stakkestad, J.A., Reginster, J.Y., Felsenberg, D., Christiansen, C., Reid, D.M., Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study (2006) Arthritis Rheum, 54, pp. 1838-1846. , 1:CAS:528:DC%2BD28Xms1Sjurs%3D 16729277
Cranney, A., Wells, G.A., Yetisir, E., Adami, S., Cooper, C., Delmas, P.D., Miller, P.D., Adachi, J.D., Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data (2009) Osteoporos Int, 20, pp. 291-297. , 1:CAS:528:DC%2BD1MXktVSgsQ%3D%3D 18663402
Harris, S.T., Blumentals, W.A., Miller, P.D., Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies (2008) Curr Med Res Opin, 24, pp. 237-245. , 1:CAS:528:DC%2BD1cXhvVOgtL0%3D 18047776
Sebba, A.I., Emkey, R.D., Kohles, J.D., Sambrook, P.N., Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis (2009) Bone, 44, pp. 423-427. , 1:CAS:528:DC%2BD1MXhvF2qsb8%3D 19049913
Harris, S.T., Reginster, J.Y., Harley, C., Blumentals, W.A., Poston, S.A., Barr, C.E., Silverman, S.L., Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study (2009) Bone, 44, pp. 758-765. , 1:CAS:528:DC%2BD1MXktFags7c%3D 19168160
Boonen, S., Haentjens, P., Vandenput, L., Vanderschueren, D., Preventing osteoporotic fractures with antiresorptive therapy: Implications of microarchitectural changes (2004) J Intern Med, 255, pp. 1-12. , 1:STN:280:DC%2BD2c%2FmsVShtQ%3D%3D 14687233
Miller, P.D., Epstein, S., Sedarati, F., Reginster, J.Y., Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study (2008) Curr Med Res Opin, 24, pp. 207-213. , 1:CAS:528:DC%2BD1cXhvVOgtL8%3D 18042311
Von Moos, R., Caspar, C.B., Thurlimann, B., Angst, R., Inauen, R., Greil, R., Bergstrom, B., Pecherstorfer, M., Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: A randomized, open-label study (2008) Ann Oncol, 19, pp. 1266-1270
Body, J.J., Diel, I.J., Lichinitser, M.R., Kreuser, E.D., Dornoff, W., Gorbunova, V.A., Budde, M., Bergström, B., Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (2003) Ann Oncol, 14, pp. 1399-1405. , 12954579
Watts, N.B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M.D., Barton, I.P., Van Staa, T.P., Adachi, J.D., Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk (2004) J Clin Densitom, 7, pp. 255-261. , 15319494
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., Haentjens, P., Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance (2008) J Intern Med, 264, pp. 315-332. , 1:CAS:528:DC%2BD1cXht1Omt7%2FK 18823505
Gasser, J.A., Ingold, P., Venturiere, A., Shen, V., Green, J.R., Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat (2008) J Bone Miner Res, 23, pp. 544-551. , 1:CAS:528:DC%2BD1cXltFyhsbg%3D 18072878
Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Meunier, P.J., Intravenous zoledronic acid in postmenopausal women with low bone mineral density (2002) N Engl J Med, 346, pp. 653-661. , 1:CAS:528:DC%2BD38XhsFOjsrw%3D 11870242
Bolland, M.J., Grey, A.B., Horne, A.M., Briggs, S.E., Thomas, M.G., Ellis-Pegler, R.B., Callon, K.E., Reid, I.R., Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months (2008) J Bone Miner Res, 23, pp. 1304-1308. , 1:CAS:528:DC%2BD1cXpvFyiu7c%3D 18627266
Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., Cosman, F., Cummings, S.R., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (2007) N Engl J Med, 356, pp. 1809-1822. , 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007
Recker, R.R., Delmas, P.D., Halse, J., Reid, I.R., Boonen, S., Garcia-Hernandez, P.A., Supronik, J., Eriksen, E.F., Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure (2008) J Bone Miner Res, 23, pp. 6-16. , 1:CAS:528:DC%2BD1cXhtVCmt7c%3D 17892374
Lyles, K.W., Colon-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C., Hyldstrup, L., Boonen, S., Zoledronic acid and clinical fractures and mortality after hip fracture (2007) N Engl J Med, 357, pp. 1799-1809. , 1:CAS:528:DC%2BD2sXht1Kit7nN 17878149
Colon-Emeric, C.S., Mesenbrink, P., Lyles, K.W., Pieper, C.F., Boonen, S., Delmas, P., Eriksen, E., Magaziner, J., Potential mediators of the mortality reduction with zoledronic acid after hip fracture (2009) J Bone Miner Res, , doi: 10.1359/jbmr.090704
Recker, R.R., Lewiecki, E.M., Miller, P.D., Reiffel, J., Safety of bisphosphonates in the treatment of osteoporosis (2009) Am J Med, 122, pp. 22-S32. , 1:CAS:528:DC%2BD1MXjs1KmtLc%3D 19187809
Loke, Y.K., Jeevanantham, V., Singh, S., Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis (2009) Drug Saf, 32, pp. 219-228. , 1:CAS:528:DC%2BD1MXlvFCmu7k%3D 19338379
Boonen, S., Sellmeyer, D.E., Lippuner, K., Orlov-Morozov, A., Abrams, K., Mesenbrink, P., Eriksen, E.F., Miller, P.D., Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women (2008) Kidney Int, 74, pp. 641-648. , 1:CAS:528:DC%2BD1cXpvVaiurY%3D 18509324
Weycker, D., MacArios, D., Edelsberg, J., Oster, G., Compliance with drug therapy for postmenopausal osteoporosis (2006) Osteoporos Int, 17, pp. 1645-1652. , 1:STN:280:DC%2BD28rotlahsA%3D%3D 16862397
Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Reginster, J.Y., Low incidence of anti-osteoporosis treatment after hip fracture (2008) J Bone Joint Surg Am, 90, pp. 2142-2148. , 18829912
Ettinger, M.P., Gallagher, R., MacCosbe, P.E., Medication persistence with weekly versus daily doses of orally administered bisphosphonates (2006) Endocr Pract, 12, pp. 522-528. , 17002926
Cotte, F.E., Fardellone, P., Mercier, F., Gaudin, A.F., Roux, C., Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis (2010) Osteoporos Int, 21, pp. 145-155
Khan, A.A., Sandor, G.K., Dore, E., Morrison, A.D., Alsahli, M., Amin, F., Peters, E., Compston, J.E., Bisphosphonate associated osteonecrosis of the jaw (2009) J Rheumatol, 36, pp. 478-490. , 19286860
Allen, M.R., Burr, D.B., The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data (2009) J Oral Maxillofac Surg, 67, pp. 61-70. , 19371816
Lenart, B.A., Lorich, D.G., Lane, J.M., Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate (2008) New Engl J Med, 358, pp. 1304-1306. , 1:CAS:528:DC%2BD1cXjvVarsb8%3D 18354114
Schneider, J.P., Bisphosphonates and low-impact femoral fractures: Current evidence on alendronate-fracture risk (2009) Geriatrics, 64, pp. 18-23. , 19256578
Neviaser, A.S., Lane, J.M., Lenart, B.A., Edobor-Osula, F., Lorich, D.G., Low-energy femoral shaft fractures associated with alendronate use (2008) J Orthop Trauma, 22, pp. 346-350. , 18448990
Kwek, E.B., Goh, S.K., Koh, J.S., Png, M.A., Howe, T.S., An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? (2008) Injury, 39, pp. 224-231. , 18222447
Chapurlat, R.D., Arlot, M., Burt-Pichat, B., Chavassieux, P., Roux, J.P., Portero-Muzy, N., Delmas, P., Microcrack frequency and bone turnover in osteoporotic women on long term bisphosphonates: A bone biopsy study (2007) J Bone Miner Res, 22, pp. 1502-1509. , 1:CAS:528:DC%2BD2sXhtFyhu7nJ 17824840
Stepan, J.J., Burr, D.B., Pavo, I., Sipos, A., Michalska, D., Li, J., Fahrleitner-Pammer, A., Dobnig, H., Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis (2007) Bone, 41, pp. 378-385. , 17597017
Abrahamsen, B., Eiken, P., Eastell, R., Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study (2009) J Bone Miner Res, 24, pp. 1095-1102. , 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 19113931
Dempster, D.W., Cosman, F., Parisien, M., Shen, V., Lindsay, R., Anabolic actions of parathyroid hormone on bone (1993) Endocr Rev, 14, pp. 690-709. , 1:CAS:528:DyaK2cXmvFKlug%3D%3D 8119233
Canalis, E., Giustina, A., Bilezikian, J.P., Mechanisms of anabolic therapies for osteoporosis (2007) N Engl J Med, 357, pp. 905-916. , 1:CAS:528:DC%2BD2sXpvVylurk%3D 17761594
Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Mitlak, B.H., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (2001) N Engl J Med, 344, pp. 1434-1441. , 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808
Miller, P.D., Bilezikian, J.P., Diaz-Curiel, M., Chen, P., Marin, F., Krege, J.H., Wong, M., Marcus, R., Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide (2007) J Clin Endocrinol Metab, 92, pp. 3535-3541. , 1:CAS:528:DC%2BD2sXhtVGqsrnL 17609307
McClung, M.R., San Martin, J., Miller, P.D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D.W., Eriksen, E.F., Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass (2005) Arch Intern Med, 165, pp. 1762-1768. , 1:CAS:528:DC%2BD2MXpslGgs7c%3D 16087825
Chen, P., Satterwhite, J.H., Licata, A.A., Lewiecki, E.M., Sipos, A.A., Misurski, D.M., Wagman, R.B., Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis (2005) J Bone Miner Res, 20, pp. 962-970. , 1:CAS:528:DC%2BD2MXlsFehtr0%3D 15883636
Dobnig, H., Sipos, A., Jiang, Y., Fahrleitner-Pammer, A., Ste-Marie, L.G., Gallagher, J.C., Pavo, I., Eriksen, E.F., Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy (2005) J Clin Endocrinol Metab, 90, pp. 3970-3977. , 1:CAS:528:DC%2BD2MXmtlCitrg%3D 15840739
Marcus, R., Wang, O., Satterwhite, J., Mitlak, B., The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis (2003) J Bone Miner Res, 18, pp. 18-23. , 1:CAS:528:DC%2BD3sXltFKmtQ%3D%3D 12510801
Dawson-Hughes, B., Chen, P., Krege, J.H., Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency (2007) J Clin Endocrinol Metab, 92, pp. 4630-4636. , 1:CAS:528:DC%2BD1cXmslWhtbo%3D 17911178
Lindsay, R., Scheele, W.H., Neer, R., Pohl, G., Adami, S., Mautalen, C., Reginster, J.Y., Mitlak, B.H., Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis (2004) Arch Intern Med, 164, pp. 2024-2030. , 15477438
Black, D.M., Greenspan, S.L., Ensrud, K.E., Palermo, L., McGowan, J.A., Lang, T.F., Garnero, P., Rosen, C.J., The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis (2003) N Engl J Med, 349, pp. 1207-1215. , 1:CAS:528:DC%2BD3sXns1Kmsrw%3D 14500804
Deal, C., Omizo, M., Schwartz, E.N., Eriksen, E.F., Cantor, P., Wang, J., Glass, E.V., Krege, J.H., Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial (2005) J Bone Miner Res, 20, pp. 1905-1911. , 1:CAS:528:DC%2BD2MXht1amt7nP 16234962
Ettinger, B., San Martin, J., Crans, G., Pavo, I., Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate (2004) J Bone Miner Res, 19, pp. 745-751. , 1:CAS:528:DC%2BD2cXktFGksrk%3D 15068497
Hodsman, A.B., Hanley, D.A., Ettinger, M.P., Bolognese, M.A., Fox, J., Metcalfe, A.J., Lindsay, R., Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis (2003) J Clin Endocrinol Metab, 88, pp. 5212-5220. , 1:CAS:528:DC%2BD3sXptVyns7k%3D 14602752
Greenspan, S.L., Bone, H.G., Ettinger, M.P., Hanley, D.A., Lindsay, R., Zanchetta, J.R., Blosch, C.M., Marriott, T.B., Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial (2007) Ann Intern Med, 146, pp. 326-339. , 17339618
Reginster, J.Y., Malaise, O., Neuprez, A., Bruyere, O., Strontium ranelate in the prevention of osteoporotic fractures (2007) Int J Clin Pract, 61, pp. 324-328. , 1:CAS:528:DC%2BD2sXjs1Wks7w%3D 17263720
Meunier, P.J., Roux, C., Seeman, E., Ortolani, S., Badurski, J.E., Spector, T.D., Cannata, J., Reginster, J.Y., The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis (2004) N Engl J Med, 350, pp. 459-468. , 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D 14749454
Canalis, E., Hott, M., Deloffre, P., Tsouderos, Y., Marie, P.J., The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro (1996) Bone, 18, pp. 517-523. , 1:CAS:528:DyaK28Xkslagu7k%3D 8805991
Baron, R., Tsouderos, Y., In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation (2002) Euro J Pharmacol, 450, pp. 11-17. , 1:CAS:528:DC%2BD38XmtlKjsb8%3D
Takahashi, N., Sasaki, T., Tsouderos, Y., Suda, T., S 12911-2 inhibits osteoclastic bone resorption in vitro (2003) J Bone Miner Res, 18, pp. 1082-1087. , 1:CAS:528:DC%2BD3sXkslOhsbk%3D 12817762
Hurtel-Lemaire, A.S., Mentaverri, R., Caudrillier, A., Cournarie, F., Wattel, A., Kamel, S., Terwilliger, E.F., Brazier, M., The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways (2009) J Biol Chem, 284, pp. 575-584. , 1:CAS:528:DC%2BD1cXhsFCjtLjM 18927086
Bonne Lye, E., Chabadel, A., Saltel, F., Jurdic, P., Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro (2008) Bone, 42, pp. 129-138. , 1:CAS:528:DC%2BD2sXhsVOrtr3E
Bain, S.D., Jerome, C., Shen, V., Dupin-Roger, I., Ammann, P., Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants (2009) Osteoporos Int, 20, pp. 1417-1428. , 1:CAS:528:DC%2BD1MXotlyhurg%3D 19096745
Reginster, J.Y., Seeman, E., De Vernejoul, M.C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J.P., Meunier, P.J., Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study (2005) J Clin Endocrinol Metab, 90, pp. 2816-2822. , 1:CAS:528:DC%2BD2MXkt1Wgt78%3D 15728210
Reginster, J.Y., Spector, T., Badurski, J., A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program (2002) Osteoporos Int, 13, p. 30
Reginster, J.Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M.L., Spector, T.D., Meunier, P.J., Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial (2008) Arthritis Rheum, 58, pp. 1687-1695. , 1:CAS:528:DC%2BD1cXotVOntrg%3D 18512789
Reginster, J.Y., Sawicki, A., Roces-Varela, Strontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in post menopausal osteoporotic women (2008) Osteoporos Int, 19, pp. 131-S132
Roux, C., Reginster, J.Y., Fechtenbaum, J., Kolta, S., Sawicki, A., Tulassay, Z., Luisetto, G., Meunier, P.J., Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors (2006) J Bone Miner Res, 21, pp. 536-542. , 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D 16598373
Seeman, E., Vellas, B., Benhamou, C., Aquino, J.P., Semler, J., Kaufman, J.M., Hoszowski, K., Boonen, S., Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older (2006) J Bone Miner Res, 21, pp. 1113-1120. , 1:CAS:528:DC%2BD28XntlWqu7k%3D 16813532
Seeman, E., Devogelaer, J.P., Lorenc, R., Spector, T., Brixen, K., Balogh, A., Stucki, G., Reginster, J.Y., Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia (2008) J Bone Miner Res, 23, pp. 433-438. , 1:CAS:528:DC%2BD1cXjsl2itbo%3D 17997711
Bruyere, O., Roux, C., Detilleux, J., Slosman, D.O., Spector, T.D., Fardellone, P., Brixen, K., Reginster, J.Y., Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate (2007) J Clin Endocrinol Metab, 92, pp. 3076-3081. , 1:CAS:528:DC%2BD2sXptl2hsb0%3D 17566094
Shea, B., Wells, G., Cranney, A., Zytaruk, N., Robinson, V., Griffith, L., Hamel, C., Guyatt, G., Calcium supplementation on bone loss in postmenopausal women (2004) Cochrane Database Syst Rev, pp. CD004526. , Osteoporosis Methodology Group
Osteoporosis Research Advisory Group
(2007) Question and Answers on the Safety of Protelos/Osseor (Strontium Ranelate), , http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/ Protelos_Q&A_53461307en.pdf.Accessed1Oct2008, European Medicines Agency (EMEA) Ref. EMEA/534613/2007. Available via
Grosso, A., Douglas, I., Hingorani, A., MacAllister, R., Smeeth, L., Post-marketing assessment of the safety of strontium ranelate
A novel case-only approach to the early detection of adverse drug reactions (2008) Br J Clin Pharmacol, 66, pp. 689-694. , 1:CAS:528:DC%2BD1cXhsVyntb7M 18754840
Tas, S., Simonart, T., Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): An update (2003) Dermatology, 206, pp. 353-356. , 1:STN:280:DC%2BD3s3kslCmuw%3D%3D 12771485
Sainz, M., Del Pozo, J.G., Arias, L.H., Carvajal, A., Strontium ranelate may cause alopecia (2009) BMJ, 338, p. 1494. , 19386675
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., Martin, T.J., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families (1999) Endocr Rev, 20, pp. 345-357. , 1:CAS:528:DyaK1MXktVaqtLg%3D 10368775
Li, J., Sarosi, I., Yan, X.Q., Morony, S., Capparelli, C., Tan, H.L., McCabe, S., Boyle, W.J., RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism (2000) Proc Natl Acad Sci U S A, 97, pp. 1566-1571. , 1:CAS:528:DC%2BD3cXhsFCrsL4%3D 10677500
Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Boyle, W.J., Osteoprotegerin: A novel secreted protein involved in the regulation of bone density (1997) Cell, 89, pp. 309-319. , 1:CAS:528:DyaK2sXislCgtLc%3D 9108485
Body, J.J., Greipp, P., Coleman, R.E., Facon, T., Geurs, F., Fermand, J.P., Harousseau, J.L., Bekker, P.J., A phase i study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases (2003) Cancer, 97, pp. 887-892. , 12548591
Bekker, P.J., Holloway, D.L., Rasmussen, A.S., Murphy, R., Martin, S.W., Leese, P.T., Holmes, G.B., Depaoli, A.M., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women (2004) J Bone Miner Res, 19, pp. 1059-1066. , 1:CAS:528:DC%2BD2cXlvFWrtr0%3D 15176987
Hofbauer, L.C., Khosla, S., Dunstan, C.R., Lacey, D.L., Spelsberg, T.C., Riggs, B.L., Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells (1999) Endocrinology, 140, pp. 4367-4370. , 1:CAS:528:DyaK1MXlslSqsLw%3D 10465311
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W.J., Lacey, D.L., Riggs, B.L., Role of RANK ligand in mediating increased bone resorption in early postmenopausal women (2003) J Clin Invest, 111, pp. 1221-1230. , 1:CAS:528:DC%2BD3sXjtFCrs7g%3D 12697741
McClung, M.R., Lewiecki, E.M., Cohen, S.B., Bolognese, M.A., Woodson, G.C., Moffett, A.H., Peacock, M., Bekker, P.J., Denosumab in postmenopausal women with low bone mineral density (2006) N Engl J Med, 354, pp. 821-831. , 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394
Lewiecki, E.M., Miller, P.D., McClung, M.R., Cohen, S.B., Bolognese, M.A., Liu, Y., Wang, A., Fitzpatrick, L.A., Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD (2007) J Bone Miner Res, 22, pp. 1832-1841. , 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711
Cummings, S.R., San Martin, J., McClung, M.R., Siris, E.S., Eastell, R., Reid, I.R., Denosumab for prevention of fractures in postmenopausal women with osteoporosis (2009) New Engl J Med, 361, pp. 756-765. , 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655
Brown, J.P., Prince, R.L., Deal, C., Recker, R.R., Kiel, D.P., De Gregorio, L.H., Hadji, P., Bone, H.G., Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial (2009) J Bone Miner Res, 24, pp. 153-161. , 1:CAS:528:DC%2BD1MXht1yrtbc%3D 18767928
Cummings, S., Eastell, R., Ensrud, K.E., Reid, D.M., Vukicevic, S., La Croix, A., The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial (2008) J Bone Miner Res, 23, p. 81. , Abstr. 1288
Downs, R., Moffett, A.H., Ghosh, A., Cox, D.A., Harper, K., Effects of arzoxifene on bone turnover and safety in postmenopausal women with low bone mass: Results from a 6-month phase 2 study (2008) J Bone Miner Res, 23, pp. 470-S471
Silverman, S.L., Christiansen, C., Genant, H.K., Vukicevic, S., Zanchetta, J.R., De Villiers, T.J., Constantiene, G.D., Chines, A.A., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial (2008) J Bone Miner Res, 23, pp. 1923-1934. , 1:CAS:528:DC%2BD1MXosVylsbo%3D 18665787
Stroup, G.B., Lark, M.W., Veber, D.F., Bhattacharyya, A., Blake, S., Dare, L.C., Erhard, K.F., Gowen, M., Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate (2001) J Bone Miner Res, 16, pp. 1739-1746. , 1:CAS:528:DC%2BD3MXnsVKqtrc%3D 11585335
McClung, M.R., Bone, H., Cosman, E., Roux, C., Verbruggen, N., Hustad, C., Dasilva, C., Ince, A., A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results (2008) J Bone Miner Res, 23, p. 82
Li, X., Ominski, M.S., Warmington, K.S., Morony, S., Gong, J., Cao, J., Gao, Y., Paszty, C., Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis (2009) J Bone Miner Res, 24, pp. 578-588. , 1:CAS:528:DC%2BD1MXksF2lu7c%3D 19049336